DexCom, Inc. DXCM
NASDAQ · United States · Health Technology
$86.29-0.35 (-0.40%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...
BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.